Research Brief
5-Amino-1MQ: Research Applications
🏋️ Obesity & Fat Loss
In diet-induced obese (DIO) mice, 5-Amino 1MQ (20 mg/kg SC, 3× daily, 11 days) reduced body weight by 5.1%, decreased epididymal white adipose tissue (WAT) mass by ~35% (P<0.001), and reduced adipocyte size by >30%, all without altering food intake. Plasma total cholesterol decreased ~30% (P<0.05). [2] In a longer study (32 mg/kg daily, 7 weeks), fat mass decreased by 29.3%, normalizing body composition to levels indistinguishable from age-matched lean controls. [9]
See also: AOD-9604 for related fat metabolism research.
💊 Type 2 Diabetes & Metabolic Syndrome
5-Amino 1MQ improved oral glucose tolerance and suppressed hyperinsulinemia in obese mouse models. It addresses the underlying metabolic dysfunction in white adipose tissue that drives insulin resistance. [12]
See also: Tirzepatide for related metabolic research.
💪 Muscle Regeneration & Sarcopenia
In aged (22-month) mice, 5-Amino 1MQ (10 mg/kg daily, 8 weeks) mimicked exercise effects: sedentary treated mice showed ~40% greater grip strength than untreated controls (P<0.001). Combined with exercise, grip strength increased by ~60%. Treated mice maintained a 1.8 km/day running increase at week 8, while untreated mice tapered off (P=0.0039). Intramyocellular lipid content decreased >30%. [10]
In aged (24-month) mice with acute muscle injury, treated animals showed nearly 2× greater myofiber cross-sectional area and ~70% increased peak torque (P<0.05), with enhanced muscle stem cell (MuSC) proliferation and fusion. [11]
🫁 Liver Disease (NAFLD/NASH)
Combined diet switch + 5-Amino 1MQ research application (28 days) normalized ALT and AST liver enzyme levels, reduced liver weight/size and triglyceride content, attenuated hepatic steatosis and macrophage infiltration. [12]
🧬 Duchenne Muscular Dystrophy (DMD)
Preclinical studies indicate that NNMT inhibition can improve muscle regeneration and function in DMD models by enhancing mitochondrial bioenergetics and reactivating dysfunctional muscle stem cells. [11]
🪸 Chronic Kidney Disease (CKD)
Research targeting NNMT inhibition shows potential in reducing renal fibrosis and tubular senescence, with improved kidney function and slowed disease progression in CKD models. [13]
🎯 Cancer (NNMT Overexpression)
NNMT is overexpressed in aggressive cancers including glioblastoma, ovarian cancer, and gastric cancer, driving metabolic and epigenetic remodeling that supports tumor growth. 5-Amino 1MQ is being investigated for its potential to suppress tumorigenesis, metastasis, and chemoresistance. [14]
⏳ Longevity & Anti-Aging
By elevating intracellular NAD+ levels and activating SIRT1, 5-Amino 1MQ is explored as a experimental to delay cellular aging, improve mitochondrial health, and prevent age-related physiological decline. [8]
References
- Neelakantan H, Wang HY, Vance V, et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem, 60(12), 5015–5028, 2017.
- Neelakantan H, Brightwell CR, Graber TG, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol, 147, 141–152, 2018.
- Neelakantan H, Vance V, Wetzel MD, et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem, 60(12), 5015-5028, 2017.
- Sun WD, Zhu GY, Li J, et al. Nicotinamide N-methyltransferase (NNMT): a novel experimental target for metabolic syndrome. Front Pharmacol, 15, 1410479, 2024.
- World Anti-Doping Agency (WADA). The World Anti-Doping Code International Standard: Prohibited List 2025. S0: Non-Approved Substances.
- Watowich SJ. SBIR Award: NNMT Inhibitor Development. National Institute on Aging (NIA), 2021.
- Awosemo O, Neelakantan H, Watowich SJ, et al. Development & Validation of LC–MS/MS Assay for 5-Amino-1-Methyl Quinolinium in Rat Plasma. J Pharm Biomed Anal, 204, 114255, 2021.
- Liu JR, Deng ZH, Zhu XJ, et al. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. BioMed Res Int, 2021, 9924314, 2021.
- Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition in obese mice. Sci Rep, 11(1), 5637, 2021.
- Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep, 14(1), 15554, 2024.
- Neelakantan H, Vance V, Wang HYL, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol, 163, 481–492, 2019.
- Babula J, Dimet-Wiley AL, Seyoum B, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab, 26(11), 5272–5282, 2024.
- Li XY, Pi YN, Chen Y, et al. Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy. Front Oncol, 12, 894744, 2022.
- Moody TW, Nuche-Berenguer B, Jensen RT. Cancer and NNMT overexpression in aggressive tumors. Curr Opin Endocrinol Diabetes Obes, 2022.
- Dimet-Wiley A, Sampson CM, Neelakantan H, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep, 12(1), 484, 2022.
- Dong G, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease. Acta Physiol, 2025.
- Watowich S, Neelakantan H, McHardy SF. Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof. U.S. Patent No. 12,071,409, August 27, 2024.
- Watowich S, Neelakantan H, McHardy SF. Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof. U.S. Patent No. 11,401,243, August 2, 2022.
Related Research Questions
FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.